Hydralazine Use and Risk of Vasculitis

What is the risk of vasculitis associated with hydralazine use compared with use of an angiotensin-converting enzyme inhibitor (ACE) or angiotensin receptor blocker (ARB)?This cohort study of 583 136 adults in Ontario, Canada, found that, when compared with ACE or ARB use, hydralazine was associated with a higher risk of vasculitis during follow-up. However, vasculitis events were rare in both groups.This study suggests that vasculitis associated with hydralazine is a rare event and use is unlikely to be associated with a clinically meaningful increased risk of vasculitis.

Corresponding Author: David Massicotte-Azarniouch, MD, MSc, Division of Nephrology, Department of Medicine, University of Ottawa, 1967 Riverside Dr, Box 100, Administrative Ste A217L, Ottawa, ON, Canada K1H 7W9 (damassicotte@toh.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.